Abstract

BackgroundProphylaxis with trimethoprim-sulfamethoxazole (TMP/SMP) is highly effective for the prevention of Pneumocysitis pneumonia (PCP) and recommended in patients with connective tissue diseases (CTD) undergoing high-dose corticosteroid therapy.[1] Prophylaxis with TMP-SMZ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
PII: S0022-3476(96)70048-3
Terry W Chin ... Eliezer Nussbaum
The Journal of Pediatrics | VOL. 129
Terry W Chin, et. al.Terry W Chin ... Eliezer Nussbaum
01 Dec 1996
Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy
Takahiro Nakamura ... Masayoshi Harigai
Modern Rheumatology | VOL. 15
Takahiro Nakamura, et. al.Takahiro Nakamura ... Masayoshi Harigai
01 Apr 2005
Epidemiology, Surveillance, and Prevention of Bloodstream Infections in Hemodialysis Patients
Matthew J Arduino ... Alexander J Kallen
American Journal of Kidney Diseases | VOL. 56
Matthew J Arduino, et. al.Matthew J Arduino ... Alexander J Kallen
15 Jun 2010
Prevention of Catheter-Related Blood Stream Infection: Back to Basics?
Lena M Napolitano ... Pauline K Park
Surgical Infections | VOL. 12
Lena M Napolitano, et. al.Lena M Napolitano ... Pauline K Park
20 Dec 2010
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers